Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study.

Africa Zimbabwe differentiated care differentiated service delivery people living with HIV (PLHIV) tuberculosis preventive treatment (TPT)

Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
06 2023
Historique:
received: 29 11 2022
accepted: 02 05 2023
medline: 22 6 2023
pubmed: 20 6 2023
entrez: 20 6 2023
Statut: ppublish

Résumé

Tuberculosis (TB) causes one-third of HIV-related deaths worldwide, making TB preventive treatment (TPT) a critical element of HIV programmes. Approximately 16% of people living with HIV (PLHIV) on antiretrovirals in Zimbabwe are enrolled in the Fast Track (FT) differentiated service delivery model, which includes multi-month dispensing of antiretrovirals and quarterly health facility (HF) visits. We assessed the feasibility and acceptability of utilizing FT to deliver 3HP (3 months of once-weekly rifapentine and isoniazid) for TPT by aligning TPT and HIV visits, providing multi-month dispensing of 3HP, and using phone-based monitoring and adherence support. We recruited a purposive sample of 50 PLHIV enrolled in FT at a high-volume HF in urban Zimbabwe. At enrolment, participants provided written informed consent, completed a baseline survey, and received counselling, education and a 3-month supply of 3HP. A study nurse mentor called participants at weeks 2, 4 and 8 to monitor and support adherence and side effects. When participants returned for their routine 3-month FT visit, they completed another survey, and study staff conducted a structured medical record review. In-depth interviews were conducted with providers who participated in the pilot. Participants were enrolled between April and June 2021 and followed through September 2021. Median age = 32 years (IQR 24,41), 50% female, median time in FT 1.8 years (IQR 0.8,2.7). Forty-eight participants (96%) completed 3HP in 13 weeks; one completed in 16 weeks, and one stopped due to jaundice. Most participants (94%) reported "always" or "almost always" taking 3HP correctly. All reported they were very satisfied with the counselling, education, support and quality of care they received from providers and FT service efficiency. Almost all (98%) said they would recommend it to other PLHIV. Challenges reported included pill burden (12%) and tolerability (24%), but none had difficulty with phone-based counselling or wished for additional HF-based visits. Using FT to deliver 3HP was feasible and acceptable. Some reported tolerability challenges but 98% completed 3HP, and all appreciated the efficiency of aligning TPT and HIV HF visits, multi-month dispensing and phone-based counselling. Scaling up this approach could expand TPT coverage in Zimbabwe.

Identifiants

pubmed: 37339341
doi: 10.1002/jia2.26105
pmc: PMC10281638
doi:

Substances chimiques

Isoniazid V83O1VOZ8L
Antitubercular Agents 0

Types de publication

Journal Article Review Research Support, U.S. Gov't, P.H.S. Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e26105

Subventions

Organisme : PEPFAR
Pays : United States

Informations de copyright

© 2023 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

Clin Infect Dis. 2015 Aug 15;61(4):527-35
pubmed: 25904367
Am J Prev Med. 2018 Aug;55(2):244-252
pubmed: 29910114
J Acquir Immune Defic Syndr. 2021 Feb 1;86(2):147-152
pubmed: 33136818
Clin Infect Dis. 2017 Oct 1;65(7):1085-1093
pubmed: 28575208
PLOS Glob Public Health. 2023 Mar 8;3(3):e0000909
pubmed: 36962979
Lancet Glob Health. 2017 Nov;5(11):e1080-e1089
pubmed: 29025631
Healthcare (Basel). 2022 Jan 07;10(1):
pubmed: 35052280
Clin Infect Dis. 2015 Oct 15;61(8):1322-7
pubmed: 26082504
BMC Health Serv Res. 2017 Jan 26;17(1):88
pubmed: 28126032
PLoS Med. 2021 Sep 14;18(9):e1003738
pubmed: 34520459
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
Ann Intern Med. 2017 Aug 15;167(4):248-255
pubmed: 28761946
Int J Tuberc Lung Dis. 2022 Sep 1;26(9):894-896
pubmed: 35996293
Public Health Pract (Oxf). 2020 Nov;1:100058
pubmed: 34173583
Int J Tuberc Lung Dis. 2022 Aug 1;26(8):741-746
pubmed: 35898140
AIDS Care. 2020 Jan;32(1):119-127
pubmed: 31181961
Int J Tuberc Lung Dis. 2020 Feb 1;24(2):165-169
pubmed: 32127099
Public Health Action. 2020 Sep 21;10(3):104-110
pubmed: 33134124
Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v
pubmed: 26260821
AIDS. 2016 Jun 19;30(10):1607-15
pubmed: 27243774

Auteurs

Munyaradzi P Mapingure (MP)

ICAP Zimbabwe, Harare, Zimbabwe.

Jennifer M Zech (JM)

ICAP at Columbia University, New York City, New York, USA.

Yael Hirsch-Moverman (Y)

ICAP at Columbia University, New York City, New York, USA.
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York City, New York, USA.

Martin Msukwa (M)

ICAP at Columbia University, Pretoria, South Africa.

Andrea A Howard (AA)

ICAP at Columbia University, New York City, New York, USA.
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York City, New York, USA.

Tatenda Makoni (T)

Zimbabwe Network for People Living with HIV (ZNNP+), Harare, Zimbabwe.

Clorata Gwanzura (C)

Ministry of Health and Child Care (MoHCC), Harare, Zimbabwe.

Tsitsi Apollo (T)

Ministry of Health and Child Care (MoHCC), Harare, Zimbabwe.

Charles Sandy (C)

Ministry of Health and Child Care (MoHCC), Harare, Zimbabwe.

Godfrey N Musuka (GN)

International Initiative for Impact Evaluation (3ie), New Delhi, India.

Miriam Rabkin (M)

ICAP at Columbia University, New York City, New York, USA.
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York City, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH